⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581890 | 0.94 | — | — | |
| SCHEMBL9690024 | 0.92 | CHRNB2 (0.32) | — | |
| SCHEMBL13065405 | 0.92 | CHRNB2 (0.32) | — | |
| SCHEMBL28983370 | 0.90 | CHRNB2 (0.31) | — | |
| SCHEMBL319395 | 0.88 | — | — | |
| Ethoxycarbonyl Group SCHEMBL28313613 | 0.80 | ESR2 (0.31) | — | |
| SCHEMBL5245447 | 0.79 | CHRNB2 (0.35) | — | |
| SCHEMBL1778320 | 0.77 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL9918039 | 0.76 | — | — | |
| SCHEMBL9607917 | 0.75 | CYP1A2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250101003-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | LARIO THERAPEUTICS LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4436661-A1 | SPIROCYCLIC CAV2.3 ANTAGONISTS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20070135427-A1 | Glucocorticoid receptor modulators as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135427-A1 | Glucocorticoid receptor modulators as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135427-A1 | Glucocorticoid receptor modulators as antiinflammatory agents | ROCHE PALO ALTO LLC | 2007-06-14 | — | — | US | disclosed |
| WO-2007065828-A1 | GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065828-A1 | GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-1017659-B1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
| US-6586613-B1 | Compounds such as 5-(tert-butyldimethylsiloxy)-7,7-dimethyl -4(4-fluorophenyl)-3-(hydroxy-(4-trifluorophenyl)-methyl)-2-isopropyl -5,6,7,8-tetrahydronaphthalene, used as antagonists for cholesteryl ester transferase protein; hyperlipemia | BAYER AKTIENGELLSCHAFT (DE) | 2003-07-01 | — | — | US | disclosed |
| EP-1017659-A1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER AG (DE) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014174-A1 | SUBSTITUTED TETRAHYDRONAPHTHALINE AND ANALOGOUS COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-03-25 | — | — | WO | disclosed |